![5E10 [PTA-865]](http://www.family998.com/static/images/cells-no_picture.jpg)
-
平臺(tái)編號(hào)：bio-68258
-
國(guó)際編號(hào)：CRL-2698?
-
細(xì)胞信息： 5E10 [PTA-865]
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
5E10 [PTA-865]
品系：BALB/c
數(shù)量：大量
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1 kappa
ATCC Number：CRL-2698?
運(yùn)輸方式：凍存運(yùn)輸
年限：adult
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
規(guī)格：48T Designations: 5E10 [PTA-865]
Depositors: ?Univ. Iowa Res. Fndn.
Isotype: IgG1 kappa
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Strain: BALB/c
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Age: adult
Comments:Animals were immunized with a mixture of six prostate tumor cell lines: primary cell lines, ALVA31, JCA1 and ND1; metastatic cell lines, DU145, LNCaP and PC3. [56301 ]
5E10 recognizes an antigenic determinant on the surface of normal and cancerous prostate cells but not on the surface of non-prostatic tumor cells, peripheral blood cells, bone marrow hematopoietic and stromal fibroblast cells, or endothelial cells. [56301 ]
The epitope recognized by 5E10 is extracellular. Western blot analysis demonstrates the 5E10 antigen is a transmembrane glycoprotein that has a molecular weight of about 115 Kd. [56301 ]
A culture deposited at the ATCC as PTA-865 in October of 1999 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline.
The cured cell line is available as CRL-2698. The original patent deposit is available as PTA-865.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10 exp5 viable cells/ml. Maintain cell density between 2 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: complete growth medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
parental cell line:ATCC PTA-865
References: 56301: Weiner GJ, et al. Prostate cell surface antigen-specific antibodies. US Patent 6,207,805 dated Mar 27 2001
56302: Rokhlin OW, et al. 5E10: a prostate-specific surface-reactive monoclonal antibody. Cancer Lett. 131: 129-136, 1998. PubMed: 9851244
數(shù)量：大量
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1 kappa
ATCC Number：CRL-2698?
運(yùn)輸方式：凍存運(yùn)輸
年限：adult
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
規(guī)格：48T Designations: 5E10 [PTA-865]
Depositors: ?Univ. Iowa Res. Fndn.
Isotype: IgG1 kappa
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Strain: BALB/c
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Age: adult
Comments:Animals were immunized with a mixture of six prostate tumor cell lines: primary cell lines, ALVA31, JCA1 and ND1; metastatic cell lines, DU145, LNCaP and PC3. [56301 ]
5E10 recognizes an antigenic determinant on the surface of normal and cancerous prostate cells but not on the surface of non-prostatic tumor cells, peripheral blood cells, bone marrow hematopoietic and stromal fibroblast cells, or endothelial cells. [56301 ]
The epitope recognized by 5E10 is extracellular. Western blot analysis demonstrates the 5E10 antigen is a transmembrane glycoprotein that has a molecular weight of about 115 Kd. [56301 ]
A culture deposited at the ATCC as PTA-865 in October of 1999 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline.
The cured cell line is available as CRL-2698. The original patent deposit is available as PTA-865.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10 exp5 viable cells/ml. Maintain cell density between 2 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: complete growth medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
parental cell line:ATCC PTA-865
References: 56301: Weiner GJ, et al. Prostate cell surface antigen-specific antibodies. US Patent 6,207,805 dated Mar 27 2001
56302: Rokhlin OW, et al. 5E10: a prostate-specific surface-reactive monoclonal antibody. Cancer Lett. 131: 129-136, 1998. PubMed: 9851244
